MICARDIS^® Product Information

MICARDIS^® had been approved for the treatment of hypertension since November 1998 in the USA and since December 1998 in Europe. Today, MICARDIS^® is approved for use in over 70 countries. Key features of MICARDIS^® include:

• Highly selective inhibition of the angiotensin II receptor 1 (AT₁)
• Effective and well-tolerated anti-hypertensive medication
• Powerful 24-hour action, curbing the morning surge in blood pressure
• Effects other than blood pressure lowering
• Not a pro-drug, no active metabolites  

For more information on MICARDIS^® and MICARDISPLUS^® in the treatment of hypertension, please download and review the documents provided below.

Download the MICARDIS^®/ MICARDISPLUS^® Product Monograph (pdf)

Further information about completed and ongoing studies with MICARDIS^® is available in the Clinical Research section of this website.